Izba

Travoprost, the active ingredient in Izba, is a prostaglandin analog presented as a 0.004% ophthalmic solution for ocular use. It lowers intra‑ocular pressure and is indicated for the management of open‑angle glaucoma and ocular hypertension in adults. GNH USA supplies Izba as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Travoprost is used in ophthalmology to manage conditions that require reduction of intra‑ocular pressure. - Open‑angle glaucoma: lowers intra‑ocular pressure to slow disease progression. - Ocular hypertension: reduces elevated eye pressure to prevent development of glaucoma. - Secondary open‑angle glaucoma: helps control pressure when caused by other ocular conditions.

Travoprost may cause ocular and peri‑ocular reactions, most of which are mild and transient.

Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Eye irritation or burning sensation. - Increased eyelash length, thickness, or darkness. - Darkening of the iris color. - Blurred vision: temporary focusing changes. - Eye pain or discomfort.

Serious or Rare Side Effects: - Allergic reaction: swelling, rash, or severe itching. - Severe eye inflammation (uveitis or iritis). - Sudden vision loss or significant visual field changes. - Persistent ocular pain unresponsive to treatment. - Corneal edema or ulceration. - Systemic hypersensitivity reactions.

Before initiating Travoprost therapy, consider the following safety measures. - Monitor intra‑ocular pressure: schedule regular eye pressure checks. - Assess for ocular infections: avoid use if active conjunctivitis or keratitis is present. - Avoid contact lens wear: discontinue lenses during treatment and for several hours after instillation. - Use with caution in patients with asthma: prostaglandin analogs may exacerbate bronchospasm. - Pregnancy and lactation: safety not established; prescribe only if benefits outweigh risks. - Store at room temperature: keep bottle in original packaging, protect from light and moisture.

Travoprost may interact with other ocular or systemic agents, influencing efficacy or safety.

Major Interactions (Avoid): - Concurrent use of other prostaglandin analog eye drops: additive IOP‑lowering effect may cause excessive pressure reduction. - Beta‑blocker ophthalmic solutions: combined use can increase risk of ocular side effects such as dry eye.

Moderate Interactions (Monitor Closely): - Systemic carbonic anhydrase inhibitors (e.g., acetazolamide): may diminish Travoprost’s pressure‑lowering effect. - Non‑steroidal anti‑inflammatory eye drops: potential for increased ocular irritation. - Anticholinergic agents: may affect tear production and exacerbate dry‑eye symptoms.